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ABSTRACT
Numerous genetic variations have been found to be
related to human diseases. Significant portion
of those affect the drug response as well by
changing the protein structure and function.
Therefore, it is crucial to understand the trilateral
relationship among genomic variations, diseases
and drugs. We present the variations and drugs
(VnD), a consolidated database containing informa-
tion on diseases, related genes and genetic
variations, protein structures and drug information.
VnD was built in three steps. First, we integrated
various resources systematically to deduce
catalogs of disease-related genes, single nucleotide
polymorphisms (SNPs), protein mutations and
relevant drugs. VnD contains 137195 disease-
related gene records (13940 distinct genes) and
16586 genetic variation records (1790 distinct vari-
ations). Next, we carried out structure modeling and
docking simulation for wild-type and mutant
proteins to examine the structural and functional
consequences of non-synonymous SNPs in the
drug-related genes. Conformational changes in 590
wild-type and 4437 mutant proteins from drug-
related genes were included in our database.
Finally, we investigated the structural and biochem-
ical properties relevant to drug binding such as
the distribution of SNPs in proximal protein
pockets, thermo-chemical stability, interactions
with drugs and physico-chemical properties.
The VnD database, available at http://vnd.kobic.re.
kr:8080/VnD/ or vandd.org, would be a useful
platform for researchers studying the underlying
mechanism for association among genetic
variations, diseases and drugs.
INTRODUCTION
Discovering genetic factors affecting disorders or diseases
is crucial for understanding the pathogenesis, diagnosis
and treatment of human diseases. Previous studies
indicate that single nucleotide polymorphisms (SNPs)
are the most common type of DNA sequence variation
found in human genome, accounting for at least 1% of
the genetic differences between individuals (1,2).
In particular, non-synonymous SNPs (nsSNPs) in the
coding region of a gene can alter the function or structure
of protein by changing amino acids or introducing a
premature stop codon (3). Conformational changes
in these proteins are major targets for drug development.
Indeed, drug response to these genetic variations
has emerged to be a major subject in the ﬁeld of pharma-
cogenomics with the combined use of genetics and
functional genomics data. Information on SNPs and
structural changes in disease-related proteins is thus
important in biomedical studies, diagnostics and drug
development (4).
Both public and commercial databases exist to provide
information on relationship between genetic variants and
drug targets. Such public efforts are represented by
GenoWatch (5), IDBD (6), DrugBank (7) and
SuperDrug (8). The GenoWatch and IDBD databases
contain information about speciﬁc diseases and a
browser for disease–gene association studies. DrugBank
contains details on drugs such as drug target and action,
and SuperDrug provides three-dimensional (3D) struc-
tures and conformers of drugs. Although each database
has its own objectives, they provide information of limited
scope such as disease-associated genes, genetic variations
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The commercial sector, led by the World Drug Index
(9), Chemistry, Manufacturing and Controls (CMC) (10)
and the MDL Drug Data Report (11), provides more
comprehensive coverage. However, they are usually very
expensive and accessible only by private commercial
entities.
Protein structure modeling and docking simulations
require computational power and experts. To our
knowledge, no public resource is available to cover the
structural aspect of disease proteins taking their genetic
variations into account. Furthermore, effect of genetic
variations on docking with drugs would be valuable
information for drug development.
Here, we present a database, variations and drugs
(VnD), which provides comprehensive information on
diseases-related genes, their genetic variations, protein
structure modeling and docking simulations. More
speciﬁcally, available information is as follows: (i) a
comprehensive catalog of disease-related genes, proteins
and drugs; (ii) structural changes caused by nsSNPs in
disease-related genes; (iii) their consequences in drug bind-
ing using docking simulation such as AutoDock (12),
Dock (13) and Fred (14) programs; (iv) distribution of
nsSNPs near the structural pockets in disease-related
proteins; and (v) functional effects of SNPs known to be
related to common diseases from association studies.
DATABASE DESIGN AND CONTENT
To build the VnD database, we developed an automatic
pipeline as shown in Figure 1. It consists of three main
steps: (i) collection of disease-related genetic variations
and proteins from public disease databases using
ontology-based uniﬁcation of disease terms, (ii) structure
modeling for both wild-type and nsSNP mutant proteins
and (iii) analysis of protein structures and identiﬁcation of
potential drug binding sites.
Collection of genetic variations associated with diseases
Disease term uniﬁcation. We extracted disease terms from
two disease databases: OMIM (15) and GAD (16).
Unfortunately, these databases use highly inconsistent
terminology to describe the same disease. For example,
141 slightly different disease descriptions exist for
‘Parkinson’s disease’. Therefore, we used the Uniﬁed
Medical Language System (UMLS) (17), which contains
medical subject headings (MeSHs) and clinical terms
from the systematized nomenclature of medicine to stand-
ardize the disease terms. The disease terms in OMIM and
GAD were mapped on the concept unique identiﬁer (CUI)
in UMLS (18) taking disease synonyms into consideration.
Through this uniﬁcation procedure, we obtained 36109
disease terms, which were then mapped to 3898 CUIs
(see Supplementary Table S1 for statistics).
Figure 1. The workﬂow of the VnD database.
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candidate genes associated with diseases or disorders
based on genomic positions and gene names. To cover
the name space of disease-related genes, we extracted
40234 gene names from the HUGO Gene Nomenclature
Committee (HGNC) (19) and the NCBI Gene database
(20). We integrated the genome annotation data as well
from various sources: NCBI’s Entrez Gene (20), RefSeq
mRNA from the UCSC table track (21) and protein in-
formation from UniProt (22). RefSeq mRNAs were
mapped to genes, and 85510 proteins were linked to
genes using the BLAST (23) search. Ultimately, we
obtained 13940 disease-related genes and 10883
disease-related UniProt proteins (Supplementary
Table S2).
Collection of disease-related genetic variations. As a source
of genetic variations, we used the databases of dbSNP (24)
and JSNP (25). Representative SNPs were mapped onto
genes and proteins based on the SNP loci and identiﬁer
(rs numbers). Total number of representative SNPs was
over 14.5-million. The number of SNPs in the genic region
was 5766 017, where 91038 SNPs were non-synonymous.
Among the amino acid changes caused by nsSNPs,
changes in glycine affect protein structure and function
most dramatically. Glycines at certain position are
strongly conserved evolutionarily due to the size restric-
tion in protein structure. Mutations at such sites would
affect the structure and function of the protein signiﬁcant-
ly (26). We examined the mutation spectrum of amino
acids changes caused by nsSNPs (see the website for
detailed result), and found a total of 5034 (6.2%) glycine
changes due to nsSNPs. In an effort to predict the
functional aspects of these nsSNPs, we have analyzed
the disease risk for 91038 nsSNPs using polymorphism
phenotyping (PolyPhen) (27).
Modeling structural changes in protein due to genetic
variations
To predict structural changes in the drug-related proteins,
we have selected 2486 proteins out of 10883 disease-
related proteins that showed sequence similarity over
95% identity with the drug target sequences in the
DrugBank database. Search for structural templates for
homology modeling was carried out using the BLASTP
and PSI-BLAST methods with the minimum percent
identity of 60% for the proteins in the PDB structure
database (28). We ﬁltered out templates with less than
100 amino acids. This procedure produced the structural
templates for 601 drug-related proteins.
Among the candidate templates that covered the nsSNP
positions, we selected the template with the highest
identity as the primary template. Then the secondary-
structure alignment, which is the input for Modeller, was
carried out using the local PSI-Pred. Next, we performed
3D structural modeling for drug-related proteins using
Modeller (version 9v7) with a single template. Modeller
automatically constructs an all-atom 3D model using one
or more alignments between the query sequence and the
homologous protein sequences of known structure (29).
Finally, we determined the best 3D structural model
based on the highest stability energy score (z-score).
To examine the structural changes due to amino acid
substitution, we generated 4020 mutant proteins at known
nsSNP sites. Structural modeling for mutant proteins was
carried out in a similar fashion using the same template as
the wild-type proteins (see Supplementary Figure S1 for
more details). In summary, we constructed 3D structural
models for 590 wild-type proteins and 4437 mutant
proteins from 538 proteins considering the disease-related
nsSNPs (see Supplementary Table S3).
Analysis of protein structural changes and docking
simulation
We have analyzed the difference in structural stability
between wild-type and mutant proteins. The G score
of each mutant versus wild-type proteins was calculated
using the I-mutant program (version 2.0). This program
calculates the free energy difference to estimate the
stability change due to mutations (30). Positive G
scores indicate an increased stability. Large values for
G (absolute value >1) may indicate signiﬁcant struc-
tural changes, which could affect the drug binding by
changing the pocket size or shape (30,31).
Previous studies have reported that protein functions
are highly dependent on physical, chemical and geometric
features of pockets on the surface of the protein (32,33).
Changes in pocket size or stability due to nsSNPs can
affect the interactions between target proteins and
ligands. Thus, nsSNPs close to the structural pockets are
likely to have deleterious effects to be the cause of disease
(34) or differences in drug metabolism. To identify the
SNP distribution near the pockets, we analyzed the
pockets in protein structure using the LIGSITE, which
calculates the pocket size and potential ligand-binding
sites by the protein–solvent–protein method (35).
We examined the pocket sizes up to 10000A ˚ 3, allowing
overlap of maximum three pockets. Most pockets were
found to be in the range between 20 and 4000A ˚ 3. More
than 50% of nsSNPs were located inside the ﬁrst two
largest pockets.
We also calculated the distances between nsSNPs sites
and the structural pockets. It was found that 767 (17%),
2176 (49%) and 3192 (71%) nsSNPs were located within
pockets, 5A ˚ from pockets and 10A ˚ from pockets, respect-
ively. Because atoms within 5–6A ˚ are able to interact
with each other (36), these SNPs can inﬂuence interactions
between the target protein and ligands.
In an effort to provide the structural picture of drug
binding, we performed the docking simulations between
the drug with the target and the mutant proteins. Three
public programs—AutoDock (version 4.0), Dock (version
6.0) and Fred (version 2.0), were used with the default
options and we obtained 981 docking results.
WEB INTERFACE
The VnD web page supports four types of search for user
convenience—protein, gene, SNP identiﬁer and disease.
Example outputs from the VnD are shown in Figure 2.
Nucleic Acids Research, 2011,Vol.39, Database issue D941In the protein menu, users can input a protein ID
(UniProt or PDB) and obtain its structural properties,
changes by nsSNP(s) and ligand docking information
from three public programs. When the number of
pockets is clicked, users can observe information about
the pockets located in the target protein. Clicking the
‘structure view’ link allows users to observe the protein
structure with the Jmol visualization software (http://
jmol.sourceforge.net) and download its 3D structural
information.
Figure 2. Query table results and graphic viewer. (a) The server displays information on structures of wild-type and mutant proteins and drug
docking found as results for a protein query. The ‘distance between pocket and SNP’ column indicates a pocket located close to a SNP and the
distance between a pocket and SNP. The ‘structure view’ column provides the structures of the wild-type and SNP mutant proteins and docking with
ligands. (b) Clicking on the gene symbol in the results table (a) allows the user to see the SNP distribution located in the gene structure, protein and
disease information.
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distribution and location in the query gene, related
protein information and the relevant disease information
as shown in Figure 2b. By clicking the ‘No. of SNPs’ in the
‘Gene Information’ table, information on transcripts and
SNP markers is displayed in the GMOD genome browser
(37). This would facilitate the recognition of disease-
related genetic features such as SNPs within the
promoter region or near the splice sites (38).
In the SNP menu, users can obtain detailed information
on the SNP including the disease risk estimated from
PolyPhen. One can also explore the structural changes in
related proteins if the query SNP is nonsynonymous.
In addition, the VnD web interface provides a tree view
of the disease terms in the UMLS concepts. Currently, the
tree view of disease terms consists of 23 top disease terms
having an average of ﬁve or six sub classes.
To demonstrate the usefulness of the VnD server, we
provide the b-2 adrenergic receptor protein (P07550) as an
example case. The output pages in Figure 2 can be classi-
ﬁed in three categories: (i) physical properties and
conformational changes due to nsSNPs in the query
protein; (ii) query protein and drug target protein infor-
mation and (iii) drug ligands and side effect information.
Speciﬁcally, this query protein is associated with obesity,
diabetes, parasitic infection and asthma. The 3D structure
and the number of functional sites in the protein are also
available in the output. Furthermore, changes in chemical
and physical properties such as energy stability caused by
six disease-related nsSNPs are also shown. Remarkably,
one of the nsSNPs (rs56100672) causes an amino acid
substitution (G257R) that changes a small, hydrophobic
residue glycine into a polar, bulky, and positively charged
residue. The 3D structural models for wild-type and
mutant proteins are shown in Supplementary Figure S2.
It shows that the pocket size is reduced signiﬁcantly from
214 to 170A ˚ 3. This size reduction and changes in the
pocket shape may have some relationship with the
disease and drug susceptibility which need further
studies. Therefore, users can observe how the disruption
of the surface pocket may affect the protein function and
explore its relationship with the molecular causes of a
disease or different drug susceptibilities among
individuals.
The VnD database server is composed of a web
interface and a MySQL (version 5.0.45) database manage-
ment system. The web interface is implemented in static
HTML pages, JSP and Java (version 1.6.0_20). MySQL is
used to store the disease-related and drug information.
CONCLUSION
We have constructed a comprehensive database that
provides information on genetic variations of disease-
related genes and their structural and functional
consequences in the aspect of drug target proteins. The
effects of non-synonymous SNPs in disease- and drug-
related genes were of special focus. We carried out
diverse analyses for wild-type and mutant proteins,
which include homology modeling, docking, disease risk
assessment and analysis on pockets and structural
features. Results from all these analyses were integrated
into a user-friendly website that would facilitate a
mechanistic understanding of trilateral relationships
among the genetic variations, diseases and drugs.
The number of disease- and drug-related genes is
rapidly increasing partly due to the recent advances in
the genome-wide association studies (GWAS). The list
of disease-related mutations is expanding as well, as the
next-generation sequencing (NGS) techniques become a
routine practice. The VnD database will continue to
serve as the platform site to explore the relationship
between genetic variations and drug effects based on
structural modeling and docking simulation.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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